Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Repatha lowers death risk by 20% in high-risk patients without prior heart attack or stroke.
AMGN
$431.77
-$0.65 -0.15%

Repatha lowers death risk by 20% in high-risk patients without prior heart attack or stroke.

Market News
31 Aug 2026
PRNewsWire
View Source
Bullish
pluang ai news

Amgen's Repatha (evolocumab) significantly reduced all-cause and cardiovascular death risk by 20% in over 12,000 high-risk patients without previous heart attack or stroke, according to the Phase 3 VESALIUS-CV trial. The benefit emerged after 1.5 years and continued through 4.6 years of follow-up, highlighting Repatha's role in preventing major cardiovascular events and extending life. Additional analyses showed early reduction in heart attacks and fewer subsequent cardiovascular events, supporting intensive LDL cholesterol lowering. Real-world studies revealed many high-risk patients remain undertreated, emphasizing the need for earlier, aggressive lipid management.

More News (AMGN)

TEZSPIRE shows lasting symptom and disease improvement in eosinophilic esophagitis through 52 weeks

TEZSPIRE shows lasting symptom and disease improvement in eosinophilic esophagitis through 52 weeks

Amgen and AstraZeneca announced that TEZSPIRE (tezepelumab-ekko) demonstrated significant and sustained improvements in eosinophilic esophagitis (EoE) patients in the Phase 3 CROSSING trial, with benefits maintained through 52 weeks. The drug improve...

Company Fundamentals
Bullish
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App